Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity

International Journal of Molecular Sciences
Salinee JantrapiromSaranyapin Potikanond

Abstract

Neuronal insulin resistance is a significant feature of Alzheimer's disease (AD). Accumulated evidence has revealed the possible neuroprotective mechanisms of antidiabetic drugs in AD. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog and an antidiabetic agent, has a benefit in improving a peripheral insulin resistance. However, the neuronal effect of liraglutide on the model of neuronal insulin resistance with Alzheimer's formation has not been thoroughly investigated. The present study discovered that liraglutide alleviated neuronal insulin resistance and reduced beta-amyloid formation and tau hyperphosphorylation in a human neuroblostoma cell line, SH-SY5Y. Liraglutide could effectively reverse deleterious effects of insulin overstimulation. In particular, the drug reversed the phosphorylation status of insulin receptors and its major downstream signaling molecules including insulin receptor substrate 1 (IRS-1), protein kinase B (AKT), and glycogen synthase kinase 3 beta (GSK-3β). Moreover, liraglutide reduced the activity of beta secretase 1 (BACE-1) enzyme, which then decreased the formation of beta-amyloid in insulin-resistant cells. This indicated that liraglutide can reverse the defect of phosphorylation status of i...Continue Reading

References

Dec 16, 1992·Biochimica Et Biophysica Acta·S E PlyteJ R Woodgett
Aug 28, 1998·Journal of Neural Transmission·L FrölichP Riederer
Dec 17, 1998·Trends in Cell Biology·E M Mandelkow, E Mandelkow
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·TracyAnn PerryNigel H Greig
Jan 8, 2003·Journal of Alzheimer's Disease : JAD·TracyAnn Perry, Nigel H Greig
Aug 20, 2003·Nature Medicine·Matthew J DuringColin N Haile
Apr 20, 2004·European Journal of Pharmacology·Francois TrudeauGuy Massicotte
May 6, 2004·Journal of Molecular Neuroscience : MN·Robert Vassar
Oct 13, 2004·Neurology·Jose A LuchsingerRichard Mayeux
Dec 14, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Lixia ZhaoGreg M Cole
Feb 20, 2007·Circulation Research·Mhairi C Towler, D Grahame Hardie
Sep 13, 2008·Molecular and Cellular Endocrinology·Jens Juul HolstCarolyn F Deacon
Feb 3, 2009·Acta Neuropathologica·Khalid IqbalInge Grundke-Iqbal
Apr 19, 2011·Journal of Molecular Endocrinology·Kenneth Siddle
Apr 29, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Paula L McCleanChristian Hölscher
Jun 20, 2012·Journal of Alzheimer's Disease : JAD·Jian-Zhi WangKhalid Iqbal
Sep 5, 2012·Nature Reviews. Endocrinology·Juris J Meier
Dec 4, 2012·The Journal of Clinical Investigation·Philip T T LyWeihong Song
Dec 5, 2012·Advances in Physiology Education·Peter M Thulé
Oct 10, 2013·Alzheimer's Research & Therapy·Xiaojie Zhang, Weihong Song
Oct 12, 2013·Journal of Neurochemistry·Mohit K SharmaChristian Hölscher
Feb 13, 2014·Current Medical Research and Opinion·Sosale R Aravind
Mar 31, 2015·Journal of Alzheimer's Disease : JAD·Erika J StarksBarbara B Bendlin

❮ Previous
Next ❯

Methods Mentioned

BETA
immunoprecipitation
protein assay
electrophoresis

Software Mentioned

Image J

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.